Hastings G Z, Francis M J, Rowlands D J, Chain B M
Department of Biology, University College, London, GB.
Eur J Immunol. 1993 Jun;23(6):1340-5. doi: 10.1002/eji.1830230623.
Human rhinovirus serotypes (HRV) fall into two distinct groups, major and minor, by virtue of their cell receptor-binding ability. In this study minor receptor-binding group viruses are demonstrated to bind directly to cells of the murine immune system, including lymphoid dendritic cells which act as antigen-presenting cells, although they do not produce a productive infection in murine cells. This binding is specific and can be blocked by other serotypes of minor-group HRV. Pre-treatment of HRV 1A, a minor-group virus, with HRV 1A-specific antibodies inhibited the cellular proliferation of murine virus primed T helper cells, whereas antibody treatment of HRV 15, a non-binding major serotype, gave no inhibition. The cell binding ability of minor-group HRV played a role in the overall immunogenicity of this virus group, which was shown to be enhanced compared to the immunogenicity of major-group viruses in mice.
人鼻病毒血清型（HRV）根据其细胞受体结合能力可分为两个不同的组，即主要组和次要组。在本研究中，次要受体结合组病毒被证明可直接结合小鼠免疫系统的细胞，包括作为抗原呈递细胞的淋巴样树突状细胞，尽管它们在小鼠细胞中不会产生增殖性感染。这种结合是特异性的，可被次要组HRV的其他血清型阻断。用HRV 1A特异性抗体预处理次要组病毒HRV 1A可抑制小鼠病毒致敏的T辅助细胞的细胞增殖，而对非结合性主要血清型HRV 15进行抗体处理则无抑制作用。次要组HRV的细胞结合能力在该病毒组的整体免疫原性中发挥了作用，与主要组病毒在小鼠中的免疫原性相比，其免疫原性有所增强。
